epitope mapping at the N-terminus of Dmp1 of mouse origin
recommended for detection of Dmp1 (also designated cyclin D binding myb-like transcription factor 1) of mouse, rat and human origin by WB, IF and ELISA; also reactive with additional species, including equine, canine, bovine, porcine and avian
blocking peptide, sc-6552 P
TransCruz reagent for Gel Supershift and ChIP applications, sc-6552 X, 200 µg/0.1 ml
Dmp1 Background Information The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy terminus of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate. A second member of the Myb proto-oncogene family, B-Myb, encodes another sequence-specific DNA binding protein. Studies suggest that B-Myb expression rescues cells from p53-induced G1 arrest mediated by p21. Dmp1 (also designated cyclin D binding myb-like transcription factor 1) has also been identified as a Myb-like transcription factor. It contains three tandem Myb repeats and has been shown to be a substrate for cyclin D-dependent kinases.
